NEC baby formula lawsuits are getting traction as families file product liability lawsuits against the manufacturers. But do you know how it all began? It began with medical malpractice lawsuits that parents filed against the doctors who prescribed Similac and Enfamil for their premature babies. Lawsuits resulted from the 1990s reports that found a higher risk associated with formula products. Now, there are more than five hundred lawsuits against the manufacturers of Similac and Enfamil, Mead Johnson, and Abbott Laboratories.
As of August 1, 2024, 538 NEC baby formula lawsuits are pending in multidistrict litigation (MDL). However, the test trial for NEC baby formula in the MDL is set to begin on May 5 next year (in 2025). More lawsuits are expected against the manufacturers.
Mother files baby formula lawsuit after death of her son
If you are closely following news, updates, and information related to NEC baby formula lawsuits, we continue to update this page with the latest updates and happenings. Let’s explore the timeline.
August 2024
Finally, August 2024 brought some good news in the NEC lawsuit payout as an Illinois mother and her daughter, Robynn, received $485 million in damages after the later developed NEC and diagnosis for the same. Robynn is said to have consumed Abbott Laboratories’ formula. A St. Louis jury awarded the mother two different compensations: $95 million for compensatory damage and $400 million in punitive damages.
July 2024
In further NEC lawsuit update 2024, a jury in St. Louis, Missouri, heard the lawsuit of a mother and her daughter, Robynn. The jury seemed convinced that the duo had suffered a lot and found that Abbott failed to warn parents, hospitals, and doctors about the risks associated with the Abbott premature infant formula. This is a significant turn of events as this is the second consecutive lawsuit to go to trial. The first trial took place in March, during which the jury awarded a $60 million verdict against Reckitt.
June 2024
More emphasis is placed on medical and feeding records scrutiny to ensure the plaintiffs used the product from birth through discharge and can quickly establish product usage. It followed a warning that failing to comply with these protocols, the plaintiff may have to face dismissal of their petition from the lawsuits.